Kay Olmstead
Direttore/Membro del Consiglio presso BENO TNR, INC.
Profilo
Kay Olmstead is the founder and current CEO & Director of Nano PharmaSolutions, Inc., a company founded in 2019.
She is also currently a Director at BENO TNR, Inc.
Posizioni attive di Kay Olmstead
| Società | Posizione | Inizio |
|---|---|---|
| BENO TNR, INC. | Direttore/Membro del Consiglio | - |
Nano Pharmasolutions, Inc.
 Nano Pharmasolutions, Inc. Pharmaceuticals: MajorHealth Technology Nano Pharmasolutions, Inc. is a pharmaceutical company based in an undisclosed location. Nano Pharmasolutions is developing a dry powder for inhalation (DPI) formulation of remedesivir to fight COVID-19. The American company's platform is based on physical vapor deposition (PVD) technology, which allows them to make drug nanoparticles with no excipients or solvents. These nanodrug particles can be used in various forms such as pills, nasal sprays, creams/salves, inhalers, and eye drops. The private company's nanotransformer™ technology can create an e-8 torr vacuum, and it uses carrier solids selected from hydrophilic pharmaceutical excipients to deposit vapor phase drugs as nanoparticles on fast-moving carriers. The company was founded by Kay Olmstead, Saeyeon Lee, Seok-Keun Koh, and Kay Olmstead has been the CEO since incorporation. | Fondatore | 01/06/2019 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| BENO TNR, INC. | Technology Services |
| Aziende private | 1 |
|---|---|
Nano Pharmasolutions, Inc.
Nano Pharmasolutions, Inc. Pharmaceuticals: MajorHealth Technology Nano Pharmasolutions, Inc. is a pharmaceutical company based in an undisclosed location. Nano Pharmasolutions is developing a dry powder for inhalation (DPI) formulation of remedesivir to fight COVID-19. The American company's platform is based on physical vapor deposition (PVD) technology, which allows them to make drug nanoparticles with no excipients or solvents. These nanodrug particles can be used in various forms such as pills, nasal sprays, creams/salves, inhalers, and eye drops. The private company's nanotransformer™ technology can create an e-8 torr vacuum, and it uses carrier solids selected from hydrophilic pharmaceutical excipients to deposit vapor phase drugs as nanoparticles on fast-moving carriers. The company was founded by Kay Olmstead, Saeyeon Lee, Seok-Keun Koh, and Kay Olmstead has been the CEO since incorporation. | Health Technology |
- Borsa valori
- Insiders
- Kay Olmstead
